Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 110 clinical trials
Polatuzumab Vedotin Rituximab Ifosfamide Carboplatin and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic …

  • 0 views
  • 10 Oct, 2021
  • 2 locations
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

The investigators propose a phase II single-arm study on using stereotactic body radiation therapy in combination with durvalumab for inoperable/unresectable hepatocellular carcinoma. In addition, the investigators will also measure the change in number and intensity of PD-L1-positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab and …

anticoagulants
progressive disease
neutrophil count
pet scan
serum bilirubin
  • 0 views
  • 15 Jun, 2021
  • 1 location
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied. Cladribine is designed to interfere with the cell's …

blast cells
azacitidine
myeloid leukemia
hydroxyurea
decitabine
  • 12 views
  • 21 Nov, 2021
  • 1 location
Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

This phase II trial of the impact of clinicogenetic risk-stratified management on outcomes of acute myeloid leukemia in older patients is to determine the rate of complete remission and mortality at 90 days in the entire cohort of older patients (≥60 years) with newly diagnosed acute myeloid leukemia, who receive …

remission
idarubicin
treatment related aml
azacitidine
daunorubicin
  • 8 views
  • 11 Aug, 2022
  • 1 location
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma (Lemon-T)

This study is to evaluate the efficacy and safety of lenalidomide maintenance therapy in patients with T-cell lymphoma who have undergone more than one treatment or relapsed after treatment and who acquired a response of more than a partial response after rescue chemotherapy. This is a phase 2 clinical trial.

  • 0 views
  • 08 Feb, 2022
  • 1 location
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor. With the increase of age, the incidence of patients over 60 years old can reach 50%, whose 5-year overall survival rate was less than 20%. With the application of …

imatinib
prednisone
philadelphia chromosome
benzene ring
tyrosine
  • 0 views
  • 08 Apr, 2022
  • 1 location
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (SCCLG-M5)

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin …

  • 0 views
  • 20 Apr, 2022
  • 9 locations
A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia (ALLO-BEST)

A subject of major interest for researchers, clinicians, patients, and payers, is the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of these older patients with AML. With conventional induction chemotherapy or hypomethylating agents, the expected 2-year overall survival (OS) is less than 25% in patients with …

remission
enasidenib
cell transplantation
induction chemotherapy
consolidation therapy
  • 0 views
  • 22 Mar, 2022
  • 1 location
Local Consolidative Therapy in Colorectal Cancer

This is a Phase II randomized multisite trial to study the effect of a combination of local consolidative therapy with systemic therapy in subjects with oligometastatic colorectal cancer who have progressed on the first line of therapy.

  • 0 views
  • 09 Oct, 2021
  • 1 location
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) …

cancer chemotherapy
brain tumor
neutrophil count
stem cell transplantation
filgrastim
  • 0 views
  • 20 Jul, 2022
  • 32 locations